Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Hepatology (Baltimore, Md.)·2026
Same author

Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.

Journal of hepatology·2025
Same author

Navigating Hepatocellular Carcinoma.

Clinics in liver disease·2024
Same author

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

The New England journal of medicine·2023
Same author

Autoimmune Hepatitis: Epidemiology, Subtypes, and Presentation.

Clinics in liver disease·2023
Same author

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Alimentary pharmacology & therapeutics·2023

Related Experiment Video

Updated: Jun 25, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

What future for ribavirin?

Mitchell L Shiffman1

  • 1Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA. mshiffma@vcu.edu

Liver International : Official Journal of the International Association for the Study of the Liver
|February 12, 2009
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) treatment optimally uses peginterferon and ribavirin. Clinical trials suggest peginterferon may be removable before ribavirin in future HCV therapies.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection requires effective antiviral therapy.
  • Peginterferon and ribavirin combination therapy is the current standard of care for HCV.
  • Ribavirin's toxicity, primarily hemolytic anemia, necessitates exploring alternative treatment strategies.

Purpose of the Study:

  • To evaluate the role of ribavirin in combination therapy for chronic hepatitis C.
  • To assess the impact of ribavirin omission or suboptimal dosing on virological response.
  • To explore the potential for replacing ribavirin in future HCV treatment regimens.

Main Methods:

  • Review of clinical trial data on HCV treatment regimens.
  • Analysis of virological response rates in patients treated with and without ribavirin.
  • Assessment of adverse events, particularly hemolytic anemia, associated with ribavirin use.
  • Evaluation of treatment outcomes when ribavirin is substituted with other antiviral agents.

Main Results:

  • Omission or premature discontinuation of ribavirin significantly reduces virological response and increases relapse rates.
  • Ribavirin use, especially in combination with peginterferon, is associated with increased incidence of hemolytic anemia.
  • Replacing ribavirin with protease inhibitors alone leads to higher relapse rates and reduced sustained virological response (SVR).

Conclusions:

  • Ribavirin remains a critical component in achieving optimal virological response in current HCV treatment paradigms.
  • Peginterferon is more likely to be considered expendable in future HCV treatment strategies than ribavirin.
  • Further research is needed to determine if ribavirin can be safely removed from combination therapies with novel antiviral agents.